Haematologica

Papers
(The H4-Index of Haematologica is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”185
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma121
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients117
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation111
The first human acute myeloid leukemia genome ever fully sequenced79
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?72
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice70
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis68
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true67
Acute myeloid leukemia at first relapse: approaching the precipice66
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS64
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi63
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection61
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies59
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms59
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R56
Bipartite <i>NUP98</i>::<i>RARA</i>-E412* fusion with a <i>cis</i>-aligned ligand binding domain truncation mutation in atypical acute promyelocytic leukemia53
P59 | BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES49
P67 | TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS49
Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide48
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review48
Artificial intelligence-based quantitative bone marrow pathology analysis for myeloproliferative neoplasms48
Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? – the PRO48
Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis47
Asparaginase-associated hyperammonemia47
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of <i>TP53</i> mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.46
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies43
Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience43
Genetic testing guides therapy in children with refractory cytopenias43
An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping42
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program42
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia40
Comprehensive characterization of human bone marrow microenvironment shows age-related changes40
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers40
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response39
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells38
Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma36
1.6286969184875